Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFA003
- Development stage
- Phase 1
- Lead developer
- Conba Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TFA003 is a novel, small-molecule selective endothelin A (ETA) receptor antagonist being developed by Hangzhou Conba Pharmaceutical for the treatment of diabetic nephropathy. By selectively blocking the ETA receptor, the drug aims to reduce proteinuria, alleviate renal inflammation, and slow the progression of kidney damage in patients with diabetes. Endothelin-1 is a potent vasoconstrictor that plays a significant role in the pathogenesis of chronic kidney disease; ETA antagonism helps counteract these effects while minimizing the side effects associated with ETB receptor inhibition, such as fluid retention. The drug is part of Conba's strategic shift toward innovative pharmaceutical development in the metabolic and renal therapeutic areas.
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on TFA003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFA003.